PT3466431T - Formas cristalinas e métodos para preparação de inibidores de sglt2 - Google Patents
Formas cristalinas e métodos para preparação de inibidores de sglt2Info
- Publication number
- PT3466431T PT3466431T PT182016329T PT18201632T PT3466431T PT 3466431 T PT3466431 T PT 3466431T PT 182016329 T PT182016329 T PT 182016329T PT 18201632 T PT18201632 T PT 18201632T PT 3466431 T PT3466431 T PT 3466431T
- Authority
- PT
- Portugal
- Prior art keywords
- methods
- crystalline forms
- sglt2 inhibitors
- preparing
- preparing sglt2
- Prior art date
Links
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/26—Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D317/42—Halogen atoms or nitro radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361783128P | 2013-03-14 | 2013-03-14 | |
| US201361887504P | 2013-10-07 | 2013-10-07 | |
| US201361912252P | 2013-12-05 | 2013-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3466431T true PT3466431T (pt) | 2024-01-26 |
Family
ID=51625112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT182016329T PT3466431T (pt) | 2013-03-14 | 2014-03-10 | Formas cristalinas e métodos para preparação de inibidores de sglt2 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9573959B2 (pt) |
| EP (2) | EP2968375B1 (pt) |
| ES (2) | ES2969245T3 (pt) |
| PT (1) | PT3466431T (pt) |
| WO (1) | WO2014159151A1 (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014159151A1 (en) | 2013-03-14 | 2014-10-02 | Msd International Gmbh | Methods for preparing sglt2 inhibitors |
| WO2015177668A1 (en) | 2014-05-19 | 2015-11-26 | Pfizer Inc. | Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr |
| EP3303345A4 (en) * | 2015-05-25 | 2019-01-30 | Sun Pharmaceutical Industries Ltd | ERTUGLIFOZINE CO-CRYSTALS AND PROCESS FOR PREPARING THEM |
| WO2017134606A1 (en) * | 2016-02-05 | 2017-08-10 | Sun Pharmaceutical Industries Limited | Crystalline form of {(1r,2s,3s,4r,5s)-5-[4-chloro-3-(4-ethoxybenzyl)phenyl]-2,3,4-trihydroxy-6,8-dioxabicyclo[3.2.1]oct-1-yl}methyl acetate |
| CN105646604A (zh) * | 2016-03-01 | 2016-06-08 | 孙霖 | 埃格列净晶型b及制备方法 |
| CN107382952B (zh) * | 2017-07-13 | 2020-02-28 | 杭州科巢生物科技有限公司 | 埃格列净的制备方法及其中间体 |
| CN107857768A (zh) * | 2018-01-04 | 2018-03-30 | 威海贯标信息科技有限公司 | 一种埃格列净新晶型 |
| CN111566112B (zh) * | 2018-03-06 | 2022-02-15 | 广东东阳光药业有限公司 | 埃格列净的晶型及其制备方法 |
| EP3810623A1 (en) | 2018-06-25 | 2021-04-28 | Pharmathen S.A. | A novel process for the preparation of sglt-2 inhibitors |
| WO2020026273A1 (en) * | 2018-07-31 | 2020-02-06 | Msn Laboratories Private Limited, R&D Center | Solid forms of ertugliflozin free base and solid dispersions comprising ertugliflozin l-pyroglutamic acid. |
| WO2020143653A1 (zh) * | 2019-01-08 | 2020-07-16 | 广东东阳光药业有限公司 | 吡喃葡萄糖基衍生物的制备方法及其中间体 |
| EP4114365A1 (en) | 2020-03-05 | 2023-01-11 | KRKA, d.d., Novo mesto | Pharmaceutical composition comprising sglt2 inhibitor |
| WO2021245253A1 (en) | 2020-06-05 | 2021-12-09 | Krka, D.D., Novo Mesto | Preparation of highly pure amorphous dapagliflozin |
| WO2021260498A1 (en) * | 2020-06-22 | 2021-12-30 | Aurobindo Pharma Limited | An improved purification process for the preparation of ertugliflozin and ertugliflozin l-pyroglutamic acid co-crystal |
| US20230250121A1 (en) * | 2020-07-08 | 2023-08-10 | Sunshine Lake Pharma Co., Ltd. | Method for preparing glucopyranosyl derivatives and intermediates thereof |
| EP4206212A4 (en) | 2020-09-30 | 2024-05-22 | Beijing Creatron Institute of Pharmaceutical Research Co., Ltd. | SGLT-2 AND SARCOSINE INHIBITOR COCRYSTAL, PROCESS FOR PREPARATION THEREFOR AND USE THEREOF |
| CN114163425A (zh) * | 2021-12-20 | 2022-03-11 | 江西天戌药业有限公司 | 一种恩格列净杂质的制备方法与应用 |
| WO2024012568A1 (en) * | 2022-07-15 | 2024-01-18 | Sunshine Lake Pharma Co., Ltd. | A key intermediate for preparing glucopyranosyl derivatives and preparation method thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE607951A (fr) | 1960-09-13 | 1962-03-07 | Hoffmann La Roche | Procédé pour la préparation de dérivés de sucre |
| PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| US6683056B2 (en) | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
| OA12333A (en) * | 2000-07-19 | 2004-04-06 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids. |
| CA2429833A1 (en) | 2000-11-30 | 2002-06-06 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| US6936590B2 (en) | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| CA2445346C (en) | 2001-04-27 | 2010-04-06 | Ajinomoto Co., Inc. | N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same |
| DE10212557A1 (de) | 2002-03-14 | 2003-09-25 | Univ Schiller Jena | Verfahren zur Charakterisierung hochparallelisierter Liquidhandlingtechnik mittels Mikroplatten sowie Testkit zur Durchführung des Verfahrens |
| DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
| TWI254635B (en) | 2002-08-05 | 2006-05-11 | Yamanouchi Pharma Co Ltd | Azulene derivative and salt thereof |
| CA2512389A1 (en) | 2003-01-03 | 2004-07-29 | Bristol-Myers Squibb Company | Methods of producing c-aryl glucoside sglt2 inhibitors |
| PL1980560T3 (pl) | 2003-03-14 | 2011-11-30 | Astellas Pharma Inc | Pochodne C-glikozydowe do leczenia cukrzycy |
| JP2004300102A (ja) | 2003-03-31 | 2004-10-28 | Kissei Pharmaceut Co Ltd | 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
| PL1651658T5 (pl) | 2003-08-01 | 2020-11-30 | Mitsubishi Tanabe Pharma Corporation | Nowe związki o działaniu inhibitującym transporter zależny od sodu |
| DE502004008951D1 (de) | 2003-08-26 | 2009-03-19 | Boehringer Ingelheim Pharma | Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| EP1724278B1 (en) | 2004-03-04 | 2014-05-07 | Kissei Pharmaceutical Co., Ltd. | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs |
| CA2557801C (en) * | 2004-03-16 | 2013-06-25 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof |
| US7393836B2 (en) | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
| DE102004034690A1 (de) | 2004-07-17 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| WO2006010557A1 (de) | 2004-07-27 | 2006-02-02 | Boehringer Ingelheim International Gmbh | D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| WO2006018150A1 (de) | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| AR051446A1 (es) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
| JP2008007405A (ja) | 2004-12-07 | 2008-01-17 | Takeda Chem Ind Ltd | カルボキサミド誘導体 |
| WO2007000445A1 (en) | 2005-06-29 | 2007-01-04 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| AR059489A1 (es) | 2006-02-15 | 2008-04-09 | Boehringer Ingelheim Vetmed | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
| TW200904405A (en) | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Pharmaceutical formulations containing an SGLT2 inhibitor |
| BRPI0918841B8 (pt) * | 2008-08-28 | 2021-05-25 | Pfizer | derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos |
| JP2012528170A (ja) | 2009-05-27 | 2012-11-12 | ブリストル−マイヤーズ スクイブ カンパニー | 別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法 |
| AP3099A (en) * | 2009-11-02 | 2015-01-31 | Pfizer | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol de derivatives |
| CN102372722A (zh) | 2010-08-10 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用 |
| WO2014159151A1 (en) | 2013-03-14 | 2014-10-02 | Msd International Gmbh | Methods for preparing sglt2 inhibitors |
-
2014
- 2014-03-10 WO PCT/US2014/022243 patent/WO2014159151A1/en active Application Filing
- 2014-03-10 PT PT182016329T patent/PT3466431T/pt unknown
- 2014-03-10 EP EP14773353.9A patent/EP2968375B1/en active Active
- 2014-03-10 ES ES18201632T patent/ES2969245T3/es active Active
- 2014-03-10 US US14/777,560 patent/US9573959B2/en active Active
- 2014-03-10 EP EP18201632.9A patent/EP3466431B1/en active Active
- 2014-03-10 ES ES14773353T patent/ES2740299T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3466431A1 (en) | 2019-04-10 |
| WO2014159151A1 (en) | 2014-10-02 |
| EP2968375B1 (en) | 2019-06-12 |
| EP2968375A4 (en) | 2016-08-03 |
| EP2968375A1 (en) | 2016-01-20 |
| US20160046646A1 (en) | 2016-02-18 |
| US9573959B2 (en) | 2017-02-21 |
| ES2740299T3 (es) | 2020-02-05 |
| EP3466431B1 (en) | 2023-11-15 |
| ES2969245T3 (es) | 2024-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3466431T (pt) | Formas cristalinas e métodos para preparação de inibidores de sglt2 | |
| HK1224298A1 (zh) | 晶體溴結構域抑制劑 | |
| ZA201601906B (en) | Methods and systems for seed variety selection | |
| SG11201505498YA (en) | Method for preparing polybutene | |
| HK1205214A1 (zh) | 鑽土設備及鑽土方法 | |
| EP2970037A4 (en) | PROCESS FOR THE PREPARATION OF ALKYLFURANES | |
| HUE050754T2 (hu) | Eljárás granulált vetõmag elõállítására és granulált vetõmag | |
| ZA201602066B (en) | Methods for improving plant growth | |
| SG11201505494TA (en) | Adjustable fracturing system | |
| ZA201604113B (en) | Siliceous composition and method for obtaining same | |
| EP2981339A4 (en) | SYSTEMS AND METHOD FOR ADVANCED BETTING | |
| HK1212353A1 (en) | Method for preparing coumestrol or coumestrin | |
| EP3010913A4 (en) | Piperidinolbenzimidazole derivatives as MPGE-1 inhibitors | |
| EP2975005A4 (en) | METHOD FOR PRODUCING A SUBSTITUTE | |
| HK1222661A1 (zh) | 吡喃葡萄糖基取代的吲哚脲衍生物及其作為 抑制劑的用途 | |
| EP2970188A4 (en) | NOVEL CRYSTALLINE FORMS | |
| GB201300903D0 (en) | Crystalline Form |